Last updated: 11/03/2018 16:02:22

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)CONCORD

GSK study ID
114025
See study documents
Clinicaltrials.gov ID
NCT01668667
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Trial description: Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a condition of the approval of HORIZANT tablets (NDA 022399).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

• The change from Baseline to the end of treatment in the International Restless Legs Syndrome (IRLS) Rating Scale score

Timeframe: 12 weeks

• The proportion of subjects at the end of treatment who are responders with either “much improved” or “very much improved” on the investigator-rated Clinical Global Impression of Improvement (CGI-I)

Timeframe: 12 weeks

Secondary outcomes:
Not applicable
Interventions:
Drug: gabapentin enacarbil GEn 600 mg
Drug: Placebo to match 600 mg, 450 mg, 300 mg
Drug: gabapentin enacarbil GEn 300 mg
Drug: gabapentin enacarbil GEn 450 mg
Enrollment:
501
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Restless Legs Syndrome
Product
gabapentin enacarbil
Collaborators
Not applicable
Study date(s)
June 2012 to November 2013
Type
Interventional
Phase
4

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
None
  • Men or women 18 years of age or older
  • History of RLS symptoms for at least 15 nights/month
  • History of a sleep disorder that may affect the assessment of RLS
  • History of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment
Inclusion and exclusion criteria
Inclusion criteria:
  • Men or women 18 years of age or older
  • History of RLS symptoms for at least 15 nights/month
  • Documented RLS symptoms, using the 7-day RLS Symptom Record, for at least 4 of the 7 consecutive evenings/nights during the night -Total RLS severity score of 15 or greater on the International RLS (IRLS) Rating Scale at Visit 1 and at Visit 2
  • Discontinuation of dopamine agonists and/or gabapentin , or other treatments for RLS (e.g. opioids, benzodiazepines) at least 2 weeks prior to Baseline
  • If taking any prescription medication, therapy must have been stabilized for at least 3 months prior to Screening with no anticipated changes for the duration of the study
  • Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use a highly effective method for avoiding pregnancy
  • Body mass index of 34 or below
  • Estimated creatinine clearance of ≥60 mL/min
  • Provides written consent in accordance with all applicable regulatory requirements
Exclusion criteria:
  • History of a sleep disorder that may affect the assessment of RLS -History of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment -Neurologic disease or movement disorder -Other medical conditions or drug therapy that could affect RLS efficacy assessments or may present a safety concern -Have clinically significant or unstable medical conditions -Have active suicidal plan/intent or has had active suicidal thoughts in the past 6 months; has a history of suicide attempt

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2013-14-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website